PD-1 blockade induces responses by inhibiting adaptive immune resistance
By P. Tumeh, C. Harview, J. Yearley, I. Shintaku, E. Taylor, L. Robert, B. Chmielowski, M. Spasić, G. Henry, V. Ciobanu and 16 more. Nature, 2014
6,158 citations recorded by the source corpus.
Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durable clinical responses in patients with various cancer types. One mechanism by which cancer tissues limit the host immune response is via upregulation of PD-1 ligand (PD-L1) and its ligation to PD-1 on antigen-specific CD8+ T cells (termed adaptive immune resistance). Here we show that pre-existing CD8+ T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy. We analysed samples from 46 patients with metastatic melanoma obtained before and during anti-PD-1 therapy (pembrolizumab) using quantitative immunohistochemistry, quantitative multiplex immunofluorescence, and next-generation sequencing for T-cell antigen receptors (TCRs). In serially sampled tumours, patients responding to treatment showed proliferation of intratumoral CD8+ T cells that directly correlated with radiographic reduction in tumour size. Pre-treatment samples obtained from responding patients showed higher numbers of CD8-, PD-1- and PD-L1-expressing cells at the invasive tumour margin and inside tumours, with close proximity between PD-1 and PD-L1, and a more clonal TCR repertoire. Using multivariate analysis, we established a predictive model based on CD8 expression at the invasive margin and validated the model in an independent cohort of 15 patients. Our findings indicate that tumour regression after therapeutic PD-1 blockade requires pre-existing CD8+ T cells that are negatively regulated by PD-1/PD-L1-mediated adaptive immune resistance.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/2c96ca62d538ff43fce01bc848fc018f6ae2b4a0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2016, background): “improved clinical outcomes and response to immunotherapy [4–8].”
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade (2016, neutral): “One important mechanism of resistance is the upregulation 1540 Cell 167, 1540–1554, December 1, 2016 ª 2016 Elsevier Inc. of PDL1 (Topalian et al., 2015; Tumeh et al., 2014), a ligand for the T cell inhibitory receptor PD1.”
- Deep learning in cancer diagnosis, prognosis and treatment selection (2021, background): “Infiltrating immune cell populations, such as CD4+ and CD8+ T cells, are potential important biomarkers of immunotherapy response [139, 140].”
- CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy (2017, background): “[4] Tumor-infiltrating lymphocytes are a key for good clinical outcomes and prediction of the response to existing checkpoint inhibitors.[5, 6] However, in vivo studies suggest the axis plays a tumorigenic role as well by increasing tumor proliferation and metastasis.”
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy (2018, background): “Expression of genes related to immune cytolytic activity have also been shown to be associated with clinical response to checkpoint blockade in certain tumors (13, 14).”
- Overcoming T cell exhaustion in infection and cancer (2015, background): “Another clinical trial also showed PD-L1 expression on immune cells infiltrating the tumor correlated with responsiveness to anti-PD-L1 (MPDL3280A) [29], and, further, higher levels of CD8+, PD-1+, and PD-L1+ cells at the invasive margin of the tumor before treatment correlated with positive respons”
- PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016, background): “In support of this possibility, recent clinical trials suggest that intratumoral T cell infiltration and TH1-type gene expression and a clonal TCR repertoire are associated with improved clinical responses to anti-PD therapy (47, 97).”
- Neoadjuvant checkpoint blockade for cancer immunotherapy (2020, background): “Nonetheless, true intratumoral proliferation of tumor-specific T cells upon PD-1 blockade has not yet been proven in humans, although it has been surmised from findings of increased clonality of TCRs in melanomas after anti–PD-1 therapy (30).”
- Molecular and genetic properties of tumors associated with local immune cytolytic activity (2015, positive): “Predictors of outcome have been identified in the context of spontaneous tumor immunity (Bindea et al., 2013) and immunotherapy (Herbst et al., 2014; Tumeh et al., 2014; Ji et al., 2012; Snyder et al., 2014), but there remains a need for more extensive mechanistic analyses of human tumor-immune…”